Regeneron (REGN) faces a 3% stock drop after losing an appeals case over its Eylea drug patents against Amgen (AMGN).

Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

The TALON trial in the wet form of AMD will compare brolucizumab against Eylea (aflibercept) on a range of measures, including visual acuity and treatment interval duration, to see if it can ...

They all had severe disease and a high treatment burden with an average of 10 injections with Eylea (aflibercept), a widely-used VEGF inhibitor sold by Bayer and Regeneron, in the last 12 months.

The introduction of biosimilars in the treatment of age-related macular degeneration (AMD) is raising concerns among physicians about cost-driven mandates and the autonomy to choose the best therapies ...

Amgen’s biosimilar formulation is distinct from both the Regeneron patent covering Eylea and from the other biosimilars ... a way to prepare and formulate the active ingredient, aflibercept, in a ...

The denosumab biosimilar market is poised for disruption with 3 FDA-approved biosimilars, at least 5 awaiting approval, and ...